Home LiteratureArticle Details
PMID: 16303887 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Lung cancer immunotherapy.

Clinical medicine & research ·Vol. 3 ·No. 4 ·2005-11-00 ·Pages 221-8

Raez LE, Fein S, Podack ER

Abstract

Recent insights into anti-tumor immunotherapy have led to a wave of clinical trials involving immunotherapy for lung cancer. Vaccines have evolved from nonspecific immune stimulants, like Bacillus Calmette-Guerin (BCG), to much more specific and potent strategies, some of which generate active immune responses against tumor-associated antigens. Understanding the mechanisms of anti-tumor immunity and identifying target antigens will likely improve these therapeutic strategies and provide them with a niche in the future of lung cancer therapy.

MeSH Terms
Animals Antigens, Neoplasm/chemistry BCG Vaccine/chemistry Cancer Vaccines/therapeutic use Carcinoma, Non-Small-Cell Lung/therapy Clinical Trials as Topic Female Humans Immunotherapy/methods Lung Neoplasms/therapy Male Models, Biological
Chemicals
Antigens, Neoplasm BCG Vaccine Cancer Vaccines
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Raez Luis E
Epidemiology and Public Health, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, FL 33136, USA. [email protected]
Fein Steven
Podack Eckhard R
References (61)
61 references, click to expand
  1. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.
    J Urol. 2002 May;167(5):1995-2000 PMID: 11956426
  2. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients.
    Hum Gene Ther. 2003 Nov 1;14(16):1497-510 PMID: 14577912
  3. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer.
    Clin Lung Cancer. 2001 Aug;3(1):49-57; discussion 58 PMID: 14656392
  4. Thymosin immunotherapy in patients with small cell carcinoma of the lung: correlation of in vitro studies with clinical course.
    Cancer. 1979 Mar;43(3):863-70 PMID: 218717
  5. Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS).
    Cancer. 1979 Apr;43(4):1314-9 PMID: 221088
  6. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
    Clin Cancer Res. 1999 Oct;5(10 Suppl):3259s-3267s PMID: 10541373
  7. Heat, heat shock, heat shock proteins and death: a central link in innate and adaptive immune responses.
    Immunol Lett. 2000 Sep 15;74(1):35-9 PMID: 10996625
  8. Cancer statistics, 2005.
    CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 PMID: 15661684
  9. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
    J Clin Oncol. 2004 Jul 15;22(14):2800-7 PMID: 15254047
  10. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.
    J Exp Med. 1996 Mar 1;183(3):791-800 PMID: 8642283
  11. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.
    J Natl Cancer Inst. 2004 Feb 18;96(4):326-31 PMID: 14970281
  12. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study.
    Int J Cancer. 2000 Oct 15;88(2):232-8 PMID: 11004674
  13. Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m.
    J Clin Oncol. 1997 May;15(5):2103-10 PMID: 9164224
  14. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
    J Clin Oncol. 2004 Jun 1;22(11):2122-32 PMID: 15169798
  15. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer.
    Cancer Res. 2000 Jul 1;60(13):3550-8 PMID: 10910068
  16. Combination chemoimmunotherapy for extensive non-oat cell lung cancer.
    Cancer Treat Rep. 1978 Jul;62(7):1059-63 PMID: 356968
  17. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
    Cancer. 2005 Apr 15;103(8):1670-5 PMID: 15751020
  18. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
    Immunol Lett. 2000 Sep 15;74(1):67-74 PMID: 10996630
  19. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin.
    Clin Cancer Res. 1999 Jun;5(6):1319-23 PMID: 10389914
  20. BCG immunotherapy of lung cancer in a district oncology dispensary. I. Study of 860 patients with histologic diagnosis.
    Neoplasma. 1982;29(1):93-110 PMID: 6280082
  21. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
    J Clin Oncol. 2002 Apr 15;20(8):2045-52 PMID: 11956264
  22. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
    Br J Cancer. 1992 Jul;66(1):155-8 PMID: 1322155
  23. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial.
    Cancer Res. 1986 Nov;46(11):5963-8 PMID: 3530442
  24. Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study.
    Eur J Cardiothorac Surg. 2004 Jan;25(1):131-4 PMID: 14690745
  25. A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma.
    Cancer Res. 2000 Sep 1;60(17):4830-7 PMID: 10987294
  26. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors.
    J Immunol. 1996 Feb 1;156(3):1117-25 PMID: 8557987
  27. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study.
    J Clin Oncol. 1985 Jul;3(7):969-76 PMID: 2991478
  28. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
    Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 PMID: 8097319
  29. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene.
    Cancer Immunol Immunother. 1993;36(1):9-17 PMID: 8422670
  30. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
    Clin Lung Cancer. 2004 Jan;5(4):231-6 PMID: 14967075
  31. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.
    Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6094-100 PMID: 15447995
  32. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.
    J Immunol. 2004 Mar 1;172(5):3289-96 PMID: 14978137
  33. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer.
    J Immunother (1991). 1992 Jul;12(1):70-3 PMID: 1322167
  34. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy.
    Ann Oncol. 2003 Mar;14(3):461-6 PMID: 12598354
  35. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
    J Immunol. 1999 Nov 15;163(10):5211-8 PMID: 10553041
  36. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
    Hiroshima J Med Sci. 2000 Mar;49(1):73-82 PMID: 10824460
  37. Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin.
    Cancer Res. 1979 Aug;39(8):3262-7 PMID: 222448
  38. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.
    Clin Cancer Res. 2004 Feb 1;10(3):916-23 PMID: 14871967
  39. BCG immunotherapy of bladder cancer: 20 years on.
    Lancet. 1999 May 15;353(9165):1689-94 PMID: 10335805
  40. Long-term results in combined-modality treatment of small cell carcinoma of the lung.
    Semin Oncol. 1978 Sep;5(3):309-13 PMID: 211642
  41. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.
    Cancer Immunol Immunother. 2000 Nov;49(9):504-14 PMID: 11092617
  42. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers.
    Cancer Sci. 2003 Nov;94(11):1003-9 PMID: 14611679
  43. B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma.
    World J Urol. 2000 Apr;18(2):157-63 PMID: 10854153
  44. Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice.
    Int J Cancer. 1998 Nov 9;78(4):480-5 PMID: 9797137
  45. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer.
    J Urol. 2001 Sep;166(3):1093-7 PMID: 11490305
  46. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results.
    Hum Gene Ther. 2003 Jul 20;14(11):1117-23 PMID: 12885350
  47. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer.
    Am J Clin Oncol. 1995 Feb;18(1):47-51 PMID: 7847259
  48. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
    N Engl J Med. 1995 Jun 22;332(25):1671-7 PMID: 7760868
  49. Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion.
    Curr Opin Mol Ther. 2002 Dec;4(6):601-5 PMID: 12596363
  50. Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection.
    J Immunol. 1999 Nov 15;163(10):5178-82 PMID: 10553037
  51. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
    Cancer Res. 1999 Jul 1;59(13):3128-33 PMID: 10397255
  52. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
    J Clin Oncol. 2003 Feb 15;21(4):624-30 PMID: 12586798
  53. Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses.
    Cancer Immunol Immunother. 2003 Jul;52(7):413-22 PMID: 12835918
  54. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
    Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90 PMID: 15365188
  55. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.
    J Clin Oncol. 1995 Jun;13(6):1328-35 PMID: 7538556
  56. Autologous dendritic cell vaccines for non-small-cell lung cancer.
    J Clin Oncol. 2004 Jul 15;22(14):2808-15 PMID: 15254048
  57. Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody.
    Curr Opin Investig Drugs. 2003 Jun;4(6):710-5 PMID: 12901230
  58. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
    Int J Oncol. 2004 Apr;24(4):909-17 PMID: 15010829
  59. Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma.
    Cancer Immunol Immunother. 2001 Jul;50(5):229-40 PMID: 11499806
  60. Immunotherapy for advanced renal cell cancer.
    Cochrane Database Syst Rev. 2005;(1):CD001425 PMID: 15674877
  61. Translational development of active immunotherapy for hematologic malignancies.
    Semin Oncol. 2003 Jun;30(3 Suppl 8):17-22 PMID: 12881808
Article Info
Journal
Clinical medicine & research
Abbr.
Clin Med Res
ISSN
1539-4182
DOI
10.3121/cmr.3.4.221
Email
[email protected]
Published
2005-11-00
Pages
221-8
Language
English
Region
United States
NLM ID
101175887
PMCID
PMC1288407
Subset
IM
Grants
NCI NIH HHS · R01-CA39201-14 · United States
External Links
PubMed source DOI: 10.3121/cmr.3.4.221 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2